Clinical Trials

Inclusion Criteria:

- Completion of a Cytokinetics trial investigating CK-3773274.

- LVEF ≥ 55% at the Screening Visit.

Exclusion Criteria:

- Has taken any investigational study drug other than CK-3773274 within 30 days prior to
screening.

- Since completion of a previous trial of CK-3773274 has:

- Developed new-onset paroxysmal or permanent atrial fibrillation requiring rhythm
restoring treatment (eg, direct-current cardioversion, ablation procedure, or
antiarrhythmic therapy) < 30 days prior to screening. Patient may re-screen for CY
6022 after 30 days if heart rate (HR) < 100 bpm and/or rhythm is stable > 30 days;

- Undergone septal reduction therapy (surgical myectomy or transcatheter alcohol
ablation) since the completion of a prior trial of CK-3773274.

- Has current obstructive coronary artery disease (> 70% stenosis documented in one or
more arteries)

- Has moderate or severe aortic valve stenosis.

- Had a confirmed LVEF <40% with an associated dose interruption during CY 6021.

- History of syncope or sustained ventricular tachyarrhythmia with exercise within 30
days prior to screening.

- History of appropriate ICD shock within 30 days prior to screening.

- Has received treatment with mavacamten.

Eligibility last updated 7/12/22. Questions regarding updates should be directed to the study team contact.